Home › Investment Analysts' Downgrades for November, 28th (ACT, AUE,...
 

Keywords :   


Investment Analysts' Downgrades for November, 28th (ACT, AUE,...

2013-11-29 11:35:04| Biotech - Topix.net

They currently have $172.00 price target on the stock. Zacks' analyst wrote, "Actavis' third quarter EPS of $2.09 was a penny short of the Zacks Consensus Estimate but up 55% y/y.

Tags: november act investment 28th

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.10Hurricane Milton Public Advisory Number 7A
07.10Summary for Hurricane Milton (AT4/AL142024)
07.10Atlantic Tropical Weather Outlook
07.10Eastern North Pacific Tropical Weather Outlook
07.10Hurricane Milton Potential Storm Surge Flooding Map
07.10Hurricane Milton Probabilistic Storm Surge Graphics
07.10Hurricane Milton Graphics
07.10Hurricane Leslie Forecast Discussion Number 19
More »